Go Pro
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel
NYSEAMERICAN:CLDI

Calidi Biotherapeutics 11/12/2024 Earnings Report

Calidi Biotherapeutics logo
$1.38 0.00 (0.00%)
As of 09/4/2026 04:10 PM Eastern
ProfileEarnings History

Calidi Biotherapeutics EPS Results

Actual EPS
-$124.80
Consensus EPS
-$163.20
Beat/Miss
Beat by +$38.40
One Year Ago EPS
N/A

Calidi Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Calidi Biotherapeutics Announcement Details

Quarter
Date
11/12/2024
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Calidi Biotherapeutics Earnings Headlines

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Trading Down 0.7% - What's Next?
September 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30997754
Calidi Biotherapeutics Reports Quarterly Results and Pipeline Progress
August 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CLDI/pressreleases/3860388/calidi-biotherapeutics-reports-quarterly-results-and-pipeline-progress/
Why the Treasury still prices gold at 42 dollars an ounce
The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades near 4,500 dollars today, a 113-to-1 gap between book value and market reality. Treasury Secretary Scott Bessent has said he wants to monetize the asset side of the balance sheet. A revaluation could add more than 1 trillion dollars to the government's books overnight. Certain gold miners still trade as if gold were under 2,000 dollars, even as prices near record highs.tc pixel
 |  Golden Portfolio (Ad)
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344982/0/en/calidi-biotherapeutics-reports-second-quarter-2026-financial-results-and-recent-business-highlights.html
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery ...
July 28, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/calidi-biotherapeutics-presents-new-data-on-cytotoxicity-and-il-15-sa-expression-in-human-and-murine-tumor-cells-at-the-american-association-for-cancer-research-drug-discovery-and-development-1036366755
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
July 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/27/3333483/0/en/calidi-biotherapeutics-presents-new-data-on-cytotoxicity-and-il-15-sa-expression-in-human-and-murine-tumor-cells-at-the-american-association-for-cancer-research-drug-discovery-and-.html
See More Calidi Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Calidi Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Calidi Biotherapeutics and other key companies, straight to your email.

About Calidi Biotherapeutics

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors. Both programs leverage the company’s proprietary immune activator to induce rapid cytokine release and recruitment of innate and adaptive immune cells at the tumor site. Preclinical studies have also demonstrated potential for a systemically delivered candidate under investigation for metastatic solid tumors. In addition, Calidi maintains a pipeline of preclinical programs exploring prophylactic and therapeutic applications against viral pathogens.

Headquartered in South San Francisco, California, Calidi Biotherapeutics was founded to advance synthetic RNA-based immunomodulators into the clinic and is led by a management team with extensive experience in immuno-oncology drug development. The company collaborates with academic partners and contract manufacturing organizations to support clinical and regulatory activities. Calidi Biotherapeutics is publicly traded on the New York Stock Exchange under the symbol CLDI.

View Calidi Biotherapeutics Profile
Earnings Tools